Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

S. K. Kumar, M. A. Dimopoulos, E. Kastritis, E. Terpos, H. Nahi, H. Goldschmidt, J. Hillengass, X. Leleu, M. Beksac, M. Alsina, A. Oriol, M. Cavo, E. M. Ocio, M. V. Mateos, E. K. O'Donnell, R. Vij, H. M. Lokhorst, N. W.C.J. Van De Donk, C. Min, T. MarkI. Turesson, M. Hansson, H. Ludwig, S. Jagannath, M. Delforge, C. Kyriakou, P. Hari, U. Mellqvist, S. Z. Usmani, D. Dytfeld, A. Z. Badros, P. Moreau, K. Kim, P. R. Otero, J. H. Lee, C. Shustik, D. Waller, W. J. Chng, S. Ozaki, J. J. Lee, J. De La Rubia, H. S. Eom, L. Rosinol, J. J. Lahuerta, A. Sureda, J. S. Kim, B. G.M. Durie

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T 0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T 0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T 0 was 3.1 years. The median number of lines of therapy before T 0 was 4 (range 3-13). The median overall survival (OS) from T 0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T 0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T 0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.

Original languageEnglish
Pages (from-to)2443-2448
Number of pages6
JournalLeukemia
Volume31
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Proteasome Inhibitors
Natural History
Multicenter Studies
Pharmaceutical Preparations
Multiple Myeloma
Confidence Intervals
Benchmarking
Survival
Alkylating Agents
Therapeutics
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., ... Durie, B. G. M. (2017). Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study. Leukemia, 31(11), 2443-2448. https://doi.org/10.1038/leu.2017.138
Kumar, S. K. ; Dimopoulos, M. A. ; Kastritis, E. ; Terpos, E. ; Nahi, H. ; Goldschmidt, H. ; Hillengass, J. ; Leleu, X. ; Beksac, M. ; Alsina, M. ; Oriol, A. ; Cavo, M. ; Ocio, E. M. ; Mateos, M. V. ; O'Donnell, E. K. ; Vij, R. ; Lokhorst, H. M. ; Van De Donk, N. W.C.J. ; Min, C. ; Mark, T. ; Turesson, I. ; Hansson, M. ; Ludwig, H. ; Jagannath, S. ; Delforge, M. ; Kyriakou, C. ; Hari, P. ; Mellqvist, U. ; Usmani, S. Z. ; Dytfeld, D. ; Badros, A. Z. ; Moreau, P. ; Kim, K. ; Otero, P. R. ; Lee, J. H. ; Shustik, C. ; Waller, D. ; Chng, W. J. ; Ozaki, S. ; Lee, J. J. ; De La Rubia, J. ; Eom, H. S. ; Rosinol, L. ; Lahuerta, J. J. ; Sureda, A. ; Kim, J. S. ; Durie, B. G.M. / Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : A multicenter IMWG study. In: Leukemia. 2017 ; Vol. 31, No. 11. pp. 2443-2448.
@article{f098b85c3c6c4dfba0c8624409f0f257,
title = "Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study",
abstract = "Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T 0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T 0 was 62 years (range 31-87); 61{\%} were males. The median duration between diagnosis and T 0 was 3.1 years. The median number of lines of therapy before T 0 was 4 (range 3-13). The median overall survival (OS) from T 0 for the entire cohort was 13 (95{\%} confidence interval (CI) 11, 15) months. At least one regimen recorded after T 0 in 462 (85{\%}) patients, with a median (95{\%} CI) progression-free survival and OS from T 0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.",
author = "Kumar, {S. K.} and Dimopoulos, {M. A.} and E. Kastritis and E. Terpos and H. Nahi and H. Goldschmidt and J. Hillengass and X. Leleu and M. Beksac and M. Alsina and A. Oriol and M. Cavo and Ocio, {E. M.} and Mateos, {M. V.} and O'Donnell, {E. K.} and R. Vij and Lokhorst, {H. M.} and {Van De Donk}, {N. W.C.J.} and C. Min and T. Mark and I. Turesson and M. Hansson and H. Ludwig and S. Jagannath and M. Delforge and C. Kyriakou and P. Hari and U. Mellqvist and Usmani, {S. Z.} and D. Dytfeld and Badros, {A. Z.} and P. Moreau and K. Kim and Otero, {P. R.} and Lee, {J. H.} and C. Shustik and D. Waller and Chng, {W. J.} and S. Ozaki and Lee, {J. J.} and {De La Rubia}, J. and Eom, {H. S.} and L. Rosinol and Lahuerta, {J. J.} and A. Sureda and Kim, {J. S.} and Durie, {B. G.M.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1038/leu.2017.138",
language = "English",
volume = "31",
pages = "2443--2448",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

Kumar, SK, Dimopoulos, MA, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, EM, Mateos, MV, O'Donnell, EK, Vij, R, Lokhorst, HM, Van De Donk, NWCJ, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, SZ, Dytfeld, D, Badros, AZ, Moreau, P, Kim, K, Otero, PR, Lee, JH, Shustik, C, Waller, D, Chng, WJ, Ozaki, S, Lee, JJ, De La Rubia, J, Eom, HS, Rosinol, L, Lahuerta, JJ, Sureda, A, Kim, JS & Durie, BGM 2017, 'Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study', Leukemia, vol. 31, no. 11, pp. 2443-2448. https://doi.org/10.1038/leu.2017.138

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : A multicenter IMWG study. / Kumar, S. K.; Dimopoulos, M. A.; Kastritis, E.; Terpos, E.; Nahi, H.; Goldschmidt, H.; Hillengass, J.; Leleu, X.; Beksac, M.; Alsina, M.; Oriol, A.; Cavo, M.; Ocio, E. M.; Mateos, M. V.; O'Donnell, E. K.; Vij, R.; Lokhorst, H. M.; Van De Donk, N. W.C.J.; Min, C.; Mark, T.; Turesson, I.; Hansson, M.; Ludwig, H.; Jagannath, S.; Delforge, M.; Kyriakou, C.; Hari, P.; Mellqvist, U.; Usmani, S. Z.; Dytfeld, D.; Badros, A. Z.; Moreau, P.; Kim, K.; Otero, P. R.; Lee, J. H.; Shustik, C.; Waller, D.; Chng, W. J.; Ozaki, S.; Lee, J. J.; De La Rubia, J.; Eom, H. S.; Rosinol, L.; Lahuerta, J. J.; Sureda, A.; Kim, J. S.; Durie, B. G.M.

In: Leukemia, Vol. 31, No. 11, 01.11.2017, p. 2443-2448.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors

T2 - A multicenter IMWG study

AU - Kumar, S. K.

AU - Dimopoulos, M. A.

AU - Kastritis, E.

AU - Terpos, E.

AU - Nahi, H.

AU - Goldschmidt, H.

AU - Hillengass, J.

AU - Leleu, X.

AU - Beksac, M.

AU - Alsina, M.

AU - Oriol, A.

AU - Cavo, M.

AU - Ocio, E. M.

AU - Mateos, M. V.

AU - O'Donnell, E. K.

AU - Vij, R.

AU - Lokhorst, H. M.

AU - Van De Donk, N. W.C.J.

AU - Min, C.

AU - Mark, T.

AU - Turesson, I.

AU - Hansson, M.

AU - Ludwig, H.

AU - Jagannath, S.

AU - Delforge, M.

AU - Kyriakou, C.

AU - Hari, P.

AU - Mellqvist, U.

AU - Usmani, S. Z.

AU - Dytfeld, D.

AU - Badros, A. Z.

AU - Moreau, P.

AU - Kim, K.

AU - Otero, P. R.

AU - Lee, J. H.

AU - Shustik, C.

AU - Waller, D.

AU - Chng, W. J.

AU - Ozaki, S.

AU - Lee, J. J.

AU - De La Rubia, J.

AU - Eom, H. S.

AU - Rosinol, L.

AU - Lahuerta, J. J.

AU - Sureda, A.

AU - Kim, J. S.

AU - Durie, B. G.M.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T 0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T 0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T 0 was 3.1 years. The median number of lines of therapy before T 0 was 4 (range 3-13). The median overall survival (OS) from T 0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T 0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T 0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.

AB - Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T 0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T 0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T 0 was 3.1 years. The median number of lines of therapy before T 0 was 4 (range 3-13). The median overall survival (OS) from T 0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T 0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T 0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.

UR - http://www.scopus.com/inward/record.url?scp=85031678437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031678437&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.138

DO - 10.1038/leu.2017.138

M3 - Article

C2 - 28620163

AN - SCOPUS:85031678437

VL - 31

SP - 2443

EP - 2448

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -